PPARG and Cognitive impairment: A promising therapeutic strategy for early AD cognitive impairment is treatment with the thiazolidinediones pioglitazone and rosiglitazone (RSG), potent and selective agonists of peroxisome proliferator-activated receptor-gamma (PPARγ) (Dickerson and Eichenbaum 2010; Harrington et al. 2007; Risner et al. 2006; Watson et al. 2005).